← Leaderboards
Sidi Chen
Yale University
$9,268,596
Attributed
$9,268,596
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.4M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,268,596 · 5
By mechanism
R01$2,976,985 · 1
DP2$2,512,500 · 1
R33$2,451,448 · 2
U54$1,327,663 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Harriet M Kluger$18,066,555
- David F Stern$15,325,663
- Peter M Glazer$37,467,142
- Eric P Winer$9,445,197
- Barbara Burtness$2,957,738
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsTumorMalignant NeoplasmsComplexHigh Throughput ScreeningGeneticGenesPhenotypeBaseScreeningCancer ModelValidationMolecularMutationGenome EditingHuman DiseaseTechnologyOrganScientistCommunitiesMouse ModelClinically RelevantVector
Grant awards (18)
Advanced development of composite gene delivery and CAR engineering systems$417,077
R33 · FY2025 · CA · contact PI
Advanced development of composite gene delivery and CAR engineering systems$396,223
R33 · FY2024 · CA · contact PI
Advanced development of composite gene delivery and CAR engineering systems$417,075
R33 · FY2023 · CA · contact PI
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression$565,095
R01 · FY2022 · CA · contact PI
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression$122,682
R01 · FY2022 · CA · contact PI
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression$576,627
R01 · FY2021 · CA · contact PI
Rapidly scalable platforms for direct in vivo screening of functional drivers in lethal cancers$407,025
R33 · FY2021 · CA · contact PI
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression$576,627
R01 · FY2020 · CA · contact PI
Rapidly scalable platforms for direct in vivo screening of functional drivers in lethal cancers$407,023
R33 · FY2020 · CA · contact PI
Core 2: In vivo cancer modeling and screening core facility$255,559
U54 · FY2020 · CA · contact PI
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression$559,327
R01 · FY2019 · CA · contact PI
Rapidly scalable platforms for direct in vivo screening of functional drivers in lethal cancers$407,025
R33 · FY2019 · CA · contact PI
Core 2: In vivo cancer modeling and screening core facility$272,379
U54 · FY2019 · CA · contact PI
High-throughput in vivo genetics for immunotherapy target discovery$2,512,500
DP2 · FY2018 · CA · contact PI
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression$576,627
R01 · FY2018 · CA · contact PI
Core 2: In vivo cancer modeling and screening core facility$260,892
U54 · FY2018 · CA · contact PI
Core 2: In vivo cancer modeling and screening core facility$267,734
U54 · FY2017 · CA · contact PI
Core 2: In vivo cancer modeling and screening core facility$271,099
U54 · FY2016 · CA · contact PI